Medical/Pharmaceuticals

Ng Teng Fong Charitable Foundation Encourages COVID-19 Vaccination Amongst Elderly Citizens

* 200 Lucky Draw Winners Received Elderly Prize * Over 50,000 Gift Packs Being Donated to Vaccinated Elderly HONG KONG, Dec. 23, 2021 /PRNewswire/ -- Ng Teng Fong Charitable Foundation Limited ('NTFCF'), the philanthropic arm of Sino Group (the 'Group'), encourages COVID-19 vaccination among ...

2021-12-23 17:55 4096

Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

CHONGQING, China, Dec. 23, 2021 /PRNewswire/ -- Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19th National Psychiatry Conference of the Chinese Medica...

2021-12-23 16:23 3936

Akeso's PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA

HONG KONG, Dec. 22, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (PCSK9 monoclonal antibody, research and development code: AK102), jointly developed by the Company and Dawnrays Biotechnology Capital (Asia) Ltd., completed patient enrollment early in a pivotal re...

2021-12-23 12:42 3220

Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China

BEIJING, Dec. 22, 2021 /PRNewswire/ -- According to Yiling Pharmaceutical's notice onThursday (UTC+8), the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued byChina's National Medical Products Administra...

2021-12-23 11:59 2345

Global Recommendations for Colon Cancer Translated into Multiple Languages as NCCN Expands Arabic Resources

New Arabic-language resources for health care providers, caregivers, and people with cancer, help set cancer care standards worldwide based on the latest evidence and expert-consensus. PLYMOUTH MEETING, Pa., Dec. 23, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alli...

2021-12-23 09:17 2809

Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046

SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 inthe United States. The patient received treatment in ENREACH-Thymic, a phase II, open label, multi-center pivotal...

2021-12-23 09:13 3829

Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma

SINGAPORE and GUANGZHOU, China and LOS ANGELES, Dec. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surf...

2021-12-23 09:00 4529

Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China

SHANGHAI, Dec. 22, 2021 /PRNewswire/ -- Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma ("Nuance"), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive a...

2021-12-23 07:44 3605

LINEPHARMA INTERNATIONAL FILES FOR MANUFACTURING, MARKETING APPROVAL OF THE ABORTION PILL IN JAPAN

LONDON and TOKYO, Dec. 23, 2021 /PRNewswire/ -- Linepharma International Ltd., a global leader in medical abortion, announced today that its subsidiary Linepharma KK has applied for manufacturing and marketing approval inJapan for its oral drug MEFEEGO™ for the medical termination of pregnancies ...

2021-12-23 05:57 3662

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise...

2021-12-23 05:54 4644

Steri-Tech Chooses CleanAir Engineering's Picarro-Based Ethylene Oxide Solution for Multi-Point Indoor Air Quality Monitoring at Commercial Sterilization Facility

Combination of Advanced Technology and Turn-Key Solutions Will Enable Accurate Ethylene Oxide Emissions Quantification and Aid in Promoting a Safer Sterilization Process SANTA CLARA, Calif. and PALATINE, Ill., Dec. 22, 2021 /PRNewswire/ --  Steri-Tech, Inc. (Steri-Tech), a Puerto Rican corporatio...

2021-12-22 23:08 3096

Deargen Annonuces Patent Application for a TNBC Target Novel Drug Candidate Using AI

* Using a self-developed AI platform, it takes only 10 weeks from the discovery of the anticancer drug targets to the discovery and synthesis of new compounds. * Proven capabilities for NCE compound discovery and design, and the establishment of a R&D center(iDear Center) to continuously deve...

2021-12-22 22:00 2443

AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy

  - Additional research centers now enrolling patients in Australia and New Zealand   - Company has achieved 50 percent of target enrollment in global Phase 3 trial LONDON, Dec. 23, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on r...

2021-12-22 21:00 2336

People-focused Highbrook Medical Centre is Now Officially Open

AUCKLAND, New Zealand, Dec. 22, 2021 /PRNewswire/ -- Highbrook Medical Centre, the newest of Health Improvement Group'sAuckland clinics, including Botany Junction ...

2021-12-22 19:12 2002

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

* US Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP™ exosome purification technology. * LEAP™ enables large-scale, clinical grade commercial production of exosomes needed to underpin the emerging field of exosome medicines. * Exopharm is seeking potential p...

2021-12-22 19:00 2613

HKU teams develop the first anti-COVID-19 stainless steel

HONG KONG, Dec. 22, 2021 /PRNewswire/ -- The project team led by Professor Mingxin HUANG at the Department of Mechanical Engineering of the Faculty of Engineering of theUniversity of Hong Kong (HKU), in collaboration with Professor Leo Lit Man POON's research team at the Centre for Immunity and ...

2021-12-22 18:09 3827

Technology central to sustainability, affordability of global healthcare industry

SINGAPORE, Dec. 21, 2021 /PRNewswire/ -- Healthcare spending saw a steep decline during the COVID-19 pandemic with associated lockdowns, restrictions, and postponement of non-essential treatments. However, the trend is expected to be short-lived as COVID-19 vaccines and testing became widely avai...

2021-12-22 14:25 2991

Wellscare to debut latest IASO-Ultra self-therapy devices at CES 2022

SEOUL, South Korea, Dec. 22, 2021 /PRNewswire/ -- Healthtech startup Wellscare is taking part in theConsumer Electronics Show 2022 (Jan. 5-8, 2022), where it will be showcasing a number of new products, including an upgraded version of its self-therapy device for herniated disk patients, IASO-...

2021-12-22 14:19 3836

TCM provides new alternatives for the fight against COVID-19

BEIJING, Dec. 21, 2021 /PRNewswire/ -- A news report by haiwainet.cn: During the 18th World Congress of Traditional Chinese Medicine held on4 December 2021, experts fromSpain, France, Australia and other countries and regions highly recognized the role of Traditional Chinese Medicine (TCM) in fig...

2021-12-22 10:15 1925

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications inEurope (including theUnited Kingdom), Latin America and Other Key Countries - Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202...

2021-12-22 09:39 4409
1 ... 595596597598599600601 ... 645